Prognostic Factors in Patients with Advanced Urothelial Cancer Who Receive Salvage Therapy

A variety of prognostic factors might help to predict outcomes of patients with metastatic urothelial cancers who undergo first-line cisplatin-based chemotherapy. In this setting, performance status and visceral metastases (known as the “Bajorin risk factors” after a key investigator) are widely accepted benchmarks for stratifying patients' risks and predicting survival (J Clin Oncol 1999; 17:3173). Whether these prognostic factors apply to patients whose disease progresses after cisplatin-based chemotherapy is unclear. The ability to determine likelihood of survival in these patients might help drive decisions about salvage therapy.

To characterize prognostic factors in patients with metastatic urothelial cancers who experienced disease pro…